Medicus Pharma Drops Sporadic BCC Program, Concentrates SkinJect on Gorlin Syndrome
核心洞察
Medicus Pharma (搜索) will end further internally sponsored development of SkinJect (搜索) in sporadic nodular basal cell carcinoma (搜索) and focus the program exclusively on Gorlin syndrome (搜索) patients with multiple BCC lesions.
The decision follows an independent commercial assessment, the completed Phase 2 SKNJCT-003 study report, principal investigator input and feedback from the FDA's Office of Orphan Products Development.
The FDA's orphan products office considers BCC in Gorlin syndrome (搜索) to be the same disease as sporadic BCC and said overall BCC prevalence exceeds the statutory threshold for the designation requests.
Medicus Pharma (搜索) is ending further development of SkinJect (搜索) for sporadic nodular basal cell carcinoma (搜索) and directing all internally sponsored development of the investigational therapy toward patients with Gorlin syndrome (搜索) who have multiple basal cell carcinoma lesions. The company said the narrower program follows a commercial, clinical and regulatory assessment and aligns with the capital-allocation strategy it outlined on Sept. 8, which concentrates resources on selected clinical development programs.
Gorlin syndrome (搜索), also known as nevoid basal cell carcinoma syndrome (搜索), is a rare inherited disorder characterized by multiple and recurrent BCCs. Patients can require repeated surgeries and other lesion-directed procedures over their lifetime. Medicus estimates that about 11,000 U.S. patients with Gorlin syndrome have active basal cell carcinoma (搜索), accounting for approximately 50,000 procedures annually.
Regulatory Feedback Shapes the Decision
The reassessment drew on an independent commercial evaluation, clinical input from the principal investigator of the Phase 2 program, and findings from the final Phase 2 Clinical Study Report. It also incorporated feedback from the FDA's Office of Orphan Products Development on Medicus' requests for Orphan Drug Designation and Rare Pediatric Disease Designation.
The orphan products office told Medicus that it considers basal cell carcinoma (搜索) occurring in Gorlin syndrome (搜索) to be the same disease as sporadic basal cell carcinoma, and noted that overall BCC prevalence exceeds the statutory threshold relevant to the designation requests. The office also identified SkinJect (搜索)'s previous clinical development in BCC outside Gorlin syndrome as relevant to determining whether the program could meet orphan-subset requirements.
Neither designation request has been closed. The FDA has held further review in abeyance while Medicus provides additional information, and the company said it intends to continue discussions with the agency and submit additional information to the orphan products office. Medicus cautioned that "there can be no assurance that the FDA will ultimately grant either of these designations."
The company believes that ending further SkinJect (搜索) development in sporadic nodular BCC addresses the issues raised by the FDA and provides a more coherent basis for pursuing the two rare-disease designations. If Orphan Drug Designation is granted and applicable requirements are met, SkinJect could qualify for benefits including certain clinical-development tax incentives, exemption from some FDA application user fees, and as much as seven years of U.S. orphan-drug exclusivity following approval.
On the pediatric designation, the FDA advised Medicus that regardless of the pending request, the company could include a request for a Rare Pediatric Disease Priority Review Voucher with an eventual marketing application if it believes SkinJect (搜索) satisfies the statutory requirements. A qualifying approval would still have to meet all applicable requirements for Medicus to receive a transferable priority review voucher.
Phase 2b Study in Gorlin Syndrome
The FDA issued a "Study May Proceed" letter in July 2026 for SKNJCT-005, an NDA-enabling, registrational Phase 2b study of SkinJect (搜索) in patients with Gorlin syndrome (搜索) and multiple BCC lesions. The program builds on the completed Phase 2 SKNJCT-003 study, which identified a 200-microgram doxorubicin-loaded dissolvable microneedle-array patch as the proposed pivotal development dose.
SkinJect (搜索) is designed to deliver doxorubicin locally through a dissolvable microneedle-array patch. Medicus is evaluating whether that approach can provide a lesion-directed treatment for Gorlin syndrome (搜索) patients who develop recurrent basal cell carcinomas and undergo repeated procedures over their lifetimes.
"Our September 8 strategic update established a clear principle for Medicus: we intend to concentrate capital where focused clinical development can create the greatest risk-adjusted value," Executive Chairman and Chief Executive Officer Raza Bokhari stated. He said the FDA-authorized, NDA-enabling SKNJCT-005 study provides a focused path to evaluate SkinJect (搜索) as a lesion-directed treatment option for Gorlin syndrome (搜索) patients while the company continues working with the FDA on its designation requests.
Commercial Assumptions Attached to the Narrower Program
Medicus is tying the narrower development strategy to a potential rare-disease pricing model. A company-commissioned 2026 commercial assessment involving physician and payer interviews modeled net pricing of approximately $25,800 per treatment, an implied U.S. total addressable market of about $1.1 billion, and potential peak U.S. revenue of roughly $383 million.
The company noted that those projections are not risk-adjusted and depend on successful clinical development, regulatory approval, reimbursement and commercial adoption.